semaglutide approval FDA Approves for Pediatric Patients The FDA's Decision to Ban

Management of alopecia areata

Its launch marked Novo Nordisk's full entry into the obesity pharmacotherapy market a market that soon exploded in size as these new GLP-1-based medications showed unprecedented efficacy (15% or more weight loss in many patients)

These include: Nausea and vomiting (very common, affecting more than 1 in 10 patients) Diarrhoea or constipation Abdominal discomfort or bloating Reduced appetite These symptoms often diminish over several weeks as the body adjusts to the medication

The company is expanding its manufacturing capabilities in India while broadening global product launches across the United States, Europe, and emerging markets

Numbness and tingling in hands, legs, and feet: These are signs of the crucial role Vitamin B12 plays in the proper functioning of the nervous system